×
Back to Agenda
Not Can, but Should: How do we WANT AI/ML to Transform Clinical Development?
Session Chair(s)
Morgan Hanger, MPA
Executive Director, Clinical Trials Transformation Initiative (CTTI), United States
Visionary leaders will debate three options for the ideal AI-transformed future state of the clinical trials enterprise. Attendees will appraise these big ideas, consider market implications, and reflect on their roles in getting us there.
Learning Objective : Evaluate three “big goals" for AI transformation of clinical development (eg, 10xing drugs reaching the market, eliminating human trial participants); Discuss the infrastructure implications of each goal (eg., with more drug candidates advancing, how will the system need to adapt?); Identify necessary, accompanying regulatory changes (eg, how will we meet increased demand for reviews?)
Speaker(s)
Tala Fakhouri, PHD, MPH
Chief AI & Regulatory Strategy Officer, Parexel, United States
Panelist
Henry Wei, MD
Executive Director, Data, Technology & Innovation, Regeneron Pharmaceuticals, United States
Panelist
Gabriel Westman, DrMed, MD, MSC
Head of Artificial Intelligence, Swedish Medical Products Agency, Sweden
Panelist
Have an account?